Latest News and Press Releases

ALLSCHWIL, Switzerland, July 12, 2005 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) (Other OTC:ALIOF) announced today that in the BREATHE-5 study evaluating the use of Tracleer(r) (bosentan) in pulmonary...

ALLSCHWIL, Switzerland, July 4, 2005 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) announced today that a study published in the July edition of the Journal of Neurosurgery suggests that clazosentan can...

ALLSCHWIL, Switzerland, June 8, 2005 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) (Other OTC:ALIOF) announced today that Tracleer(r) (bosentan) is now available upon prescription to all patients in Japan....

SAN DIEGO, May 24, 2005 (PRIMEZONE) -- Actelion Ltd (Other OTC:ALIOF) (SWX:ATLN) announced that data from almost 5,000 Tracleer(R)-treated patients amounting to 3,416 patient-years of treatment were...

ALLSCHWIL, Switzerland, May 23, 2005 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) announced today that preliminary efficacy data generated in the proof-of-concept program testing its urotensin-II receptor...

-- Total net revenue increases to CHF 146.4 million, up 45 percent compared to Q1 2004 -- Expanding PAH market results in strong Tracleer(r) sales of CHF 139.8 million -- Operating...

ALLSCHWIL/BASEL, Switzerland , April 14, 2005 (PRIMEZONE) -- At today's Annual General Meeting of Actelion Ltd (SWX:ATLN), shareholders approved the following resolutions: -- Increase of the...

ALLSCHWIL, Switerzerland, April 11, 2005 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) (Other OTC:ALIOF) announced today that the Japanese Ministry of Health, Labor and Welfare has granted formal approval...

ALLSCHWIL, Switzerland, March 15, 2005 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) (Other OTC:ALIOF) announced today that the renin alliance with Merck & Co., Inc., (NYSE:MRK) has achieved its second...

-- Formal approval expected in early April -- Market introduction foreseen for spring 2005 ALLSCHWIL, Switzerland, Feb. 28, 2005 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) today announced that is...